论文部分内容阅读
美国食品和药品管理局(FDA)于2011年5月31日对医务人员和患者发布安全警告:含屈螺酮(drospirenone)的避孕药可能增加血栓的风险。屈螺酮属于17-α螺甾内酯类孕激素(drospirenone),是具有天然黄体酮活性的人工合成化合物,其配方药也被称为第4代复方口服避孕药(COC)。它通过抑制卵泡释放、改变宫颈黏液稠度和子宫内膜形态达到可靠的避孕效果。静脉血栓栓塞
The U.S. Food and Drug Administration (FDA) issued a safety alert to healthcare providers and patients on May 31, 2011: drospirenone-containing birth control pills may increase the risk of thrombosis. Drospirenone is a 17-alpha spironolactone-type progestin (drospirenone), a synthetic compound with natural progesterone activity, and its formulation is also known as 4th Generation Compound Oral Contraception (COC). It achieves a reliable contraceptive effect by inhibiting follicle release, changing cervical mucus consistency and endometrial morphology. Venous thromboembolism